Moura Rodrigo Scaliante de, Calado Karla Lucena, Oliveira Maria Leide W, Bührer-Sékula Samira
Tropical Pathology and Public Health Institute, Federal University of Goiás, Goiás, Brazil.
Rev Soc Bras Med Trop. 2008;41 Suppl 2:11-8. doi: 10.1590/s0037-86822008000700004.
Serology using a species-specific antigen for Mycobacterium leprae, PGL-I, could be a marker for the bacterial load of patients with leprosy. Various studies have identified the potential use of serology in the classification of patients for treatment purposes, case monitoring, identification of the risk of relapse and selection of household contacts with a higher risk of contracting the disease. A systematic review of the literature was conducted and 26 articles were included in this comparative analysis. The results of the use of PGL-I serology in different situations, its limitations and possible applications were evaluated. Studies show the efficacy of PGL-I serology in the classification of patients, treatment monitoring and as a predictive test for leprosy reactions. To improve early diagnosis and follow-up of the population at greatest risk of developing leprosy, the methodologies used in the past have yet to show a favorable cost-benefit ratio, although studies indicate that the use of the test might positively influence leprosy control programs. With simple and robust techniques, the use of PGL-I serology is viable.
使用针对麻风分枝杆菌的种特异性抗原酚糖脂-1(PGL-I)进行血清学检测,可能是麻风病患者细菌载量的一个标志物。多项研究已确定血清学在麻风病患者治疗分类、病例监测、复发风险识别以及高感染风险家庭接触者选择等方面具有潜在用途。我们对文献进行了系统回顾,并将26篇文章纳入此次比较分析。评估了PGL-I血清学检测在不同情况下的使用结果、局限性及可能的应用。研究表明PGL-I血清学检测在患者分类、治疗监测以及作为麻风反应预测性检测方面具有有效性。为改善对麻风病高风险人群的早期诊断和随访,尽管研究表明该检测的使用可能对麻风病控制项目产生积极影响,但过去使用的方法尚未显示出良好的成本效益比。凭借简单且可靠的技术,PGL-I血清学检测的应用是可行的。